Passage BIO Inc
QuietPhiladelphia, PABiotechnology, HealthcareLast fund filed August 2019
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Passage BIO, Inc. | August 2019 | $110M | $110M | 15 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Saqib Islam | Quiet | Biotech & pharma | 2 | 0 |
Classified sectors of Passage BIO Inc’s own portfolio companies, based on 7 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Passage BIO Inc’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Orbimed New Horizons | 2 | Silverback Therapeutics, SpringWorks Therapeutics |
| Orbimed Partners | 2 | Silverback Therapeutics, SpringWorks Therapeutics |
| ARCH Venture Partners | 1 | Rodeo Therapeutics |
| Caduceus Capital |
| Tadataka Yamada | Quiet | Biotech & pharma, Healthcare services | 5 | 0 |
| Thomas Street Address 1 Woiwode | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 1 |
| SpringWorks Therapeutics |
| Orbimed Asia Partners | 1 | SpringWorks Therapeutics |
| Pivotal bioVenture Partners | 1 | Outpost Medicine |
| U.S Venture Partners | 1 | Silverback Therapeutics |
| Vivo Capital | 1 | Outpost Medicine |
A shared board seat: a company where filings name a Passage BIO Inc partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.